LivaNova RECOVER depression trial enrollment continues from 375 to 400 unipolar patients

LivaNova PLC

Independent Statistical Analysis Committee advised continuation of RECOVER trial enrollment from 375 to 400 unipolar patients, per protocol.
Trial includes frequent interim analyses every 25 patients to assess predictive probability of success.
Upon meeting success criteria, RCT enrollment stops and patients enter open-label longitudinal study.
Final analysis after last RCT patient completes 12 months follow-up; data to support peer-reviewed article.
Success could lead to CMS reconsideration of reimbursement for VNS Therapy for difficult-to-treat depression.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.